Navigation Links
RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
Date:9/13/2008

as been used to treat the diarrhea and flushing associated with carcinoid syndrome.

The active ingredient in Sandostatin LAR Depot, octreotide acetate, was approved in the United States in October 1988. In November 1998, the FDA approved the long-acting formulation of octreotide acetate which Novartis markets as Sandostatin LAR Depot. Through more than a decade, and 600,000 patient years of experience, Sandostatin LAR Depot has achieved a long-standing track record of sustained efficacy and a well-established safety profile.

Sandostatin LAR Depot important safety information

Adverse reactions identified in clinical studies include nausea, abdominal pain, gas, constipation, vomiting, pain on injection, high or low blood sugar levels and slow or irregular heart rate. Many patients developed gallstones, although few patients required treatment.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "potential", "to confirm", "promise", "proposed", "promising", "may", "will", or similar expressions, or by express or implied discussions regarding potential marketing approvals for RAD001 or regarding potential future revenues from RAD001. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with RAD001 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that RAD001 will be approved for sale in any market. Nor can there be any guarantee that RAD001 will achieve any particular levels of revenue in the future. In particular, management's expectations regarding RAD001 could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpe
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
2. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
3. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
4. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
11. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 HeartWare International, ... of less invasive, miniaturized circulatory support technologies that are ... that its President and Chief Executive Officer, Doug ... Genuity 35th Annual Growth Conference at 8:30 a.m. EDT ... held August 12-13, 2015 at the InterContinental Boston. ...
(Date:8/4/2015)... LOS ANGELES , Aug. 4, 2015 ... the world,s leading provider of diagnostic information services, ... announced acquisition of MemorialCare Health System,s laboratory outreach ... of the transaction, patients and physicians now have ... and network of nearly 200 patient service centers ...
(Date:8/4/2015)... SAN FRANCISCO , Aug. 4, 2015 /PRNewswire/ ... Nicki Vasquez , Ph.D., as vice president ... have a leadership role in the management of ... cancer therapeutics pipeline, including antibody-drug conjugates, bispecific antibodies ... Dr. Vasquez brings more than 22 years of ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2
... Mass., Jan. 17, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that a ... Electrophysiology demonstrates the high acute and chronic ... procedure using HeartLight EAS. The study was conducted ...
... Inc. (NYSE Amex: PTN ) announced today ... of non-dilutive funding through the New Jersey Economic Development ... New Jersey net operating losses and research and development ... Palatin Technologies received approximately $637,000 under this program. ...
Cached Medicine Technology:Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 2Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 3Journal of Cardiovascular Electrophysiology Study Shows Promising Single Ablation Procedure Outcomes With HeartLight EAS for Treatment of Atrial Fibrillation 4
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power Products acquires new ... its reach in Texas. Effective July 1st of this year, Worldwide Power Products ... With the North Texas acquisition, Worldwide Power Products (“WPP”) now services 1000 ...
(Date:8/4/2015)... ... 2015 , ... Recent studies in the United ... binge drinking among certain populations and specific locations. Researchers, who have ... trends and evidence to help facilitate health care treatment to meet current needs. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Members receiving care ... care metrics – at a cost that is nine percent lower -- than those ... Blue Shield of New Jersey’s patient-centered programs. , “The promise of patient-centered, or ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health ... kindergarten. All required immunizations are covered for members under the Healthchek program . ... aren’t caught up with their immunizations may not be allowed to attend when ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... manufacturing, label design, product packaging, and fulfillment services, joined over 200 other Long ... event was held on Tuesday, July 28th at Jones Beach State Park in ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... available in Spanish . , The ... Clinical Research of European Legislation ) a project with ... the European Directive on Clinical Trials (2001/20/EC) in all ... also has the active participation of the different stakeholders: ...
... public policy effort to boost safety , , MONDAY, July 28 ... in your town or your route to work through an ... of the need to drive safely. , Researchers at ... (CERS) developed www.saferoadmaps.org, so you can simply enter your address ...
... launches new website offering convenient http://www.terrimilen.com [Online Counseling via ... comfort of their own home or office. , ... ... provide clients with an alternative to traditional therapy which requires clients ...
... sample traced back to Mexican farm, FDA announces ... a week after uncovering the first big clue in ... that tainted jalapeno peppers had been definitively traced to ... Drug Administration gave the all-clear to jalapeno and serrano ...
... to discuss second quarter financial results -, LAVAL, ... DDSS) today announced that it will host a conference ... discuss its second quarter 2008,financial results. Labopharm will report ... approximately 7:00 a.m. the same day., To access ...
... function, increases asthma risk, studies find, , , FRIDAY, July ... actually be bad for your health, depending on what ... , Recent research suggests that exposure to cleaning products ... compound (VOC) called 1,4 dicholorobenzene (1,4 DCB), can reduce ...
Cached Medicine News:Health News:Researchers Map America's Deadliest Roads 2Health News:Online Counseling and Life Coaching Practice Launches New Website 2Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3
... Web-based and RFID-enabled location system that allows ... flow and utilization of resources throughout the ... collects patient information including location, and alerts ... experience. This information is directed to both ...
... Radianse indoor positioning solution ... of where and when ... flow through care processes. ... provides intelligence that hospitals ...
... enables healthcare facilities to provide a higher ... throughput utilizing one low cost infrastructure and ... Mobile Aspects active RFID tags, small enough ... and can house pertinent patient information such ...
VACUETTE PaediatricMulti-Sample Needle...
Medicine Products: